An alternative method to analyse the biomarker-strategy design by Kunz, Cornelia Ursula et al.
Received: 16 June 2016 Revised: 27 June 2018 Accepted: 20 July 2018
DOI: 10.1002/sim.7940
RE S EARCH ART I C L E
An alternative method to analyse the biomarker-strategy
design
Cornelia Ursula Kunz1,2,3 Thomas Jaki1 Nigel Stallard4
1Department of Mathematics and
Statistics, Lancaster University, Lancaster,
UK
2Institute of Medical Biometry and
Informatics, University of Heidelberg,
Heidelberg, Germany
3Biostatistics & Data Sciences, Boehringer
Ingelheim Pharma GmbH & Co. KG,
Ingelheim am Rhein, Germany
4Warwick Medical School, University of
Warwick, Coventry, UK
Correspondence
Cornelia Ursula Kunz, Boehringer
Ingelheim Pharma GmbH & Co. KG.
Email: cukunz@web.de
Funding information
National Institute for Health Research,
Grant/Award Number:
NIHR-SRF-2015-08-001; Medical
Research Council, Grant/Award Number:
MR/M014525/1 and MR/M005755/1
Recent developments in genomics and proteomics enable the discovery of
biomarkers that allow identification of subgroups of patients responding well to
a treatment. One currently used clinical trial design incorporating a predictive
biomarker is the so-called biomarker strategy design (or marker-based strategy
design). Conventionally, the results from this design are analysed by comparing
the mean of the biomarker-led arm with the mean of the randomised arm. Sev-
eral problems regarding the analysis of the data obtained from this design have
been identified in the literature. In this paper, we show how these problems can
be resolved if the sample sizes in the subgroups fulfil the specified orthogonality
condition. We also propose a different analysis strategy that allows definition of
test statistics for the biomarker-by-treatment interaction effect as well as for the
classical treatment effect and the biomarker effect. We derive equations for the
sample size calculation for the case of perfect and imperfect biomarker assays.
We also show that the often used 1:1 randomisation does not necessarily lead
to the smallest sample size. In addition, we provide point estimators and con-
fidence intervals for the treatment effects in the subgroups. Application of our
method is illustrated using a real data example.
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1 INTRODUCTION
The focus of modern medicine has shifted from broad spectrum treatments to targeted therapeutics leading to new chal-
lenges for the design and analysis of clinical trials. Recent developments in genomics and proteomics enable the discovery
of biomarkers that allow identification of subgroups of patients responding well to a treatment. Often, little is known
about this subset of patients until well into large-scale clinical trials.1
The impact of genomic variability is often assessed in a biomarker-based design. The general question when using any
of these designs is whether different treatments should be recommended for different subgroups of patients. Establishing
clinical relevance of a biomarker test for guiding therapy decisions requires demonstrating that it can classify patients
into distinct subgroups with different recommended managements.2 Several clinical trial designs using a biomarker to
identify subgroups of patients likely to respond to a treatment have been proposed in the literature. The most commonly
used designs are the enrichment design and the biomarker stratified design.3,4
Another currently used design incorporating a predictive biomarker is the so-called biomarker strategy design (or
marker-based strategy design).2,5,6 Within this design, patients are randomised either to have their treatment based on
the biomarker (ie, biomarker-positive patients receive a new treatment while biomarker-negative patients receive the
standard treatment) or to be randomly assigned to treatment T or control group C (see Figure 1).
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FIGURE 1 Biomarker-strategy/marker-based design
An alternative variant of the biomarker strategy design would not randomise patients in the randomised arm but treat
everyone in this arm with the control treatment.2,3,7 Although this design is a special case of the design described above
(the probability to be randomised into the treatment arm is set to 0), this special case is more frequently used.8 The main
criticism here is that a huge proportion of the patients receive the same treatment.9 Furthermore, given that all patients in
the randomised arm receive the control treatment, this variant of the biomarker-strategy design cannot establish whether
the new treatment would be beneficial for biomarker-negative patients as they all receive the control treatment.3
Conventionally, the results of a biomarker-strategy design are analysed comparing the biomarker-led arm (arm BM)
to the randomised arm (arm R) (see Figure 1). The efficiency of this analysis has been investigated.8,10 However, all crit-
icisms are focusing on special cases of the biomarker-strategy design: Firstly, they all assume that randomisation to the
biomarker-led and the randomised arm is equal. Secondly, Hoering et al8 and Young et al10 both considered the special
case of “no randomisation” in the randomised arm, which means that all patients in that arm receive the control treat-
ment. Young et al also consider the case of equal randomisation within the randomised arm. While equal randomisation
might be frequently used, it is not clear whether this minimises the sample size of the biomarker-strategy design. Fur-
thermore, Young et al investigate the efficiency of the design either if there is no treatment effect in the disease-negative
patients or if the treatment effect in the disease negative patients is in the same direction as the treatment effect for the
positive patients but only half as large.
We hence extend the previous work in the followingways: (1)We investigate the efficiency of the design if the treatment
effect in the disease-negative patients is in the opposite direction of the treatment effect for the biomarker-positive patients
and (2) we investigate optimal randomisation rules for the design in order to minimise the sample size. Furthermore,
we propose a different way to analyse the data obtained from the biomarker-strategy design. The “traditional” analysis
does not exploit all information that can be obtained from the data. Rücker11 proposed a two-stage randomised clinical
trial design, which in principle corresponds to the biomarker strategy design with the only difference that patients in the
“non-randomised arm” (ie, the biomarker-led arm) choose the treatment they prefer. However, she suggests an analysis
method that allows testing of the overall treatment effect, the self-selection effect and the preference effect. Walter et al12
derive optimal randomisation rules for the abovementioned design by Rücker. Their focus lies only on optimising the first
randomisation while they assume equal allocation to treatment and control in the randomised arm. Turner et al13 give a
sample size equation for the design proposed by Rücker. However, likeWalter et al, they also assume equal randomisation
in the randomised arm. They also assume equal variances across all arms.
The aim of this paper is to adopt the analysis method proposed by Rücker and extend it to the biomarker strategy
design by accounting for possible misclassifications using an imperfect assay. We provide equations to calculate the
sample size as well as point estimators and confidence intervals for the treatment effects in the biomarker-positive and
biomarker-negative subgroups.
2 MOTIVATING EXAMPLE
Brusselle et al14 report the results from the AZISAST trial, a multicentre randomised double-blind placebo-controlled
trial. Patients with exacerbation-prone severe asthma received low-dose azithromycin or placebo as add-on treatment to
a combination therapy of inhaled corticosteroids and long-acting 𝛽2 agonists for 6 months. The primary outcome was
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the rate of severe exacerbations and the lower respiratory tract infections (LRTI) requiring treatment with antibiotics
during the 26-week treatment phase, and one of the secondary endpoints was the forced expiratory volume in 1 second
(FEV1). For the primary endpoint as well as the abovementioned secondary endpoint, no effects were found for the over-
all population. However, opposite effects were found for the primary endpoint for patients with either eosinophilic or
non-eosinophilic severe asthma. For the secondary outcome FEV1, they report a baseline value of 80.1 (standard devia-
tion SD 21.9) for the azithromycin group and a baseline value of 84.8 (20.7) for the placebo group. They also report a mean
difference (between baseline and 26 weeks) of −0.02 for the azithromycin group and a mean difference of −0.90 for the
placebo group. They do not report the values for the two subgroups (eosinophilic or non-eosinophilic severe asthma), so
for our illustrations, we therefore assume the following values: 𝜇T+ = 90, 𝜇T− = 70, 𝜇C+ = 75, and 𝜇C− = 95. Patients
with eosinophilic severe asthma are considered “positive.” Furthermore, we assume 𝜎T+ = 𝜎T− = 𝜎C+ = 𝜎C− = 20. For a
prevalence of p = 0.5 for eosinophilic asthma, the effect in the treatment group is p𝜇T+ + (1− p)𝜇T− = 80; for the control
group, the effect is p𝜇C+ + (1−p)𝜇C− = 85; and the overall treatment effect is p𝜇T+ + (1−p)𝜇T− − (p𝜇C+ + (1−p)𝜇C−) = −5,
which roughly reflects the effects observed in the AZISAST trial.
3 NOTATION
LetN denote the total sample size (assumed to be fixed), r1 denote the fraction of patients randomised to the biomarker-led
arm, and let nBM = Nr1 denote the number of patients in the biomarker-led arm. Furthermore, let nR = N(1 − r1)
denote the number of patients in the randomised arm. Let r2 denote the fraction of patients within the randomised arm
that receive the experimental treatment and nT = N(1 − r1)r2 denote the sample size for this arm. Furthermore, let
nC = N(1 − r1)(1 − r2) denote the sample size for the control arm of the randomised arm. We assume that a block
randomisation is used so that the sample sizes nBM, nR, nT, and nC are fixed.
Within the biomarker-led arm, patients have their biomarker assessed. Due to cost, ethical, or administrative reasons,
an imperfect assay is used to determine the true biomarker status. Let p denote the prevalence of the true biomarker status
and let t and s denote the sensitivity and specificity of the biomarker assay used.Without loss of generality, we assume that
patients with an observed positive biomarker status receive the experimental treatment while patients with an observed
negative biomarker status receive the control treatment. Let nT⊕ (nC⊖) denote the number of patients with an observed
positive (negative) biomarker status. The sample sizes follow binomial distributions with nT⊕ ∼ Binomial(Nr1, p⊕) and
nC⊖ ∼ Binomial(Nr1, p⊖) with p⊕ = pt + (1 − p)(1 − s) and p⊖ = p(1 − t) + (1 − p)s = 1 − p⊕.
The primary endpoint of interest is denoted with Y and follows a normal distribution with mean 𝜇T+ and vari-
ance 𝜎2T+ for truly biomarker-positive patients receiving the experimental treatment, mean 𝜇T− and variance 𝜎
2
T−
for truly biomarker-negative patients receiving the experimental treatment, mean 𝜇C+ and variance 𝜎2C+ for truly
biomarker-positive patients receiving the control treatment, and mean 𝜇C− and variance 𝜎2C− for truly biomarker-negative
patients receiving the control treatment. Table 1 gives an overview of some of the notation used.
4 TRADITIONAL ANALYSIS
The traditional analysis of the biomarker-strategy design is to compare the mean of the biomarker-led arm 𝜇BM with the
mean of the randomised arm 𝜇R.15 The null hypotheses states thatHTA0 : 𝜇BM = 𝜇R while the alternative hypothesis states
that HTA1 : 𝜇BM ≠ 𝜇R.
TABLE 1 Notation
Biomarker (BM)-led Group
Positive BM status Negative BM status Randomised group
Treatment Index T⊕ T
True mean 𝜃T⊕ = pt𝜇T+ + (1 − p)(1 − s)𝜇T− … 𝜇T = p𝜇T+ + (1 − p)𝜇T−
Sample size nT⊕ … nT
Data ∑T⊕𝑦 = ∑nT⊕i=1 𝑦T⊕,i … ∑T𝑦 = ∑nTi=1 𝑦T,i
Control Index … C⊖ C
True mean … 𝜃C⊖ = p(1 − t)𝜇C+ + (1 − p)s𝜇C− 𝜇C = p𝜇C+ + (1 − p)𝜇C−
Sample size … nC⊖ nC
Data … ∑T⊖𝑦 = ∑nC⊖i=1 𝑦C⊖,i ∑C𝑦 = ∑nCi=1 𝑦C,i
4 KUNZ ET AL.
Let ZBM and ZR be defined as ZBM =
∑
T⊕𝑦+
∑
C⊖𝑦
Nr1
and ZR =
∑
T𝑦+
∑
C𝑦
N(1−r1)
. A test statistic for the hypothesis above is then
given by
ZBM − ZR√
V̂AR [ZBM − ZR]
. (1)
The expected value and variance of the test statistic as well as an estimator for the variance can be found in Appendix A.
4.1 Criticism
Although the biomarker strategy design is sometimes regarded as the gold standard, there is also a lot of criticism regarding
the trial design and the analysis of the data. The main problem with the traditional analysis is that it does not distinguish
between a situation where there is only an overall treatment effect (but no treatment-by-biomarker interaction effect), a
situationwhere there is only an interaction effect (but no treatment effect), and a situationwhere there is both a treatment
and an interaction effect. This “inability” leads to the following problems:
• Problem 1 “No interaction effect”: As mentioned above, the traditional analysis cannot distinguish between the
treatment and the interaction effect. If there is no interaction effect, we have 𝜇T+ − 𝜇C+ = 𝜇T− − 𝜇C− = 𝜇T• − 𝜇C•. In
this case, the expected value of the test statistic for the traditional analysis is E[𝜇BM − 𝜇R] = (tp + (1 − p)(1 − s) −
r2)(𝜇T• − 𝜇C•). So, as long as tp + (1 − p)(1 − s) − r2 ≠ 0 and 𝜇T• − 𝜇C• ≠ 0, we observe a difference between
the mean of the biomarker-led arm and the randomised arm even if there is no treatment-by-biomarker interaction
effect.
• Problem 2 “Biomarker assay not predictive”: As Freidlin, McShane, and Korn2 noted before for a design with
r2 = 0, it is still possible to observe a difference between the means even if the biomarker assay is not predictive, ie,
t = s = 0.5. In general, if t = s = 0.5, the expected difference between the two arms is (0.5− r2)(p(𝜇T+ −𝜇C+)+(1−
p)(𝜇T− − 𝜇C−)), which is the same as (0.5 − r2) times the “overall treatment effect.” Hence, we would still observe
a difference between the biomarker-led arm and the control arm (randomised arm) as long as there is an “overall
treatment effect” and 0.5 − r2 ≠ 0. If the observed difference is positive, we would recommend to use the assay to
inform about the treatment a patient should receive although the assay is not predictive.
• Problem 3 “Arbitrary randomisation”: The expected value of the test statistic for the traditional analysis depends
on the arbitrary randomisation ratio r2 since E[𝜇BM−𝜇R] = tp(𝜇T+ −𝜇C+)+(1−s)(1−p)(𝜇T− −𝜇C−)−r2(p(𝜇T+ −𝜇C+)+
(1−p)(𝜇T− −𝜇C−)). It can be shown that if r2 = (pt(𝜇T+ −𝜇C+)+ (1−p)(1− s)(𝜇T− −𝜇C−))∕(p(𝜇T+ −𝜇C+)+ (1−p)(𝜇T− −
𝜇C−)), the differences between the two means are always zero (E[𝜇BM − 𝜇R] = 0) irrespective of the values of the
other parameters.
4.2 Orthogonality condition
In the previous section, we have seen that the traditional analysis cannot distinguish between the treatment and the
interaction effect. Under Problem 1,we show that the expected value in case there is no interaction effect is E[𝜇BM − 𝜇R] =
(tp + (1 − p)(1 − s) − r2)(𝜇T• − 𝜇C•) = (p⊕ − r2)(𝜇T• − 𝜇C•). One way of solving this problem is to set r2 = p⊕. This
ensures that the traditional analysis is now a test for the interaction effect only and that if there is no interaction effect,
the expected value of the test statistic is indeed 0 (the proof can be found in Appendix A). Hence, setting r2 = pT⊕ is a
requirement in order to be able to interpret the results of the traditional analysis.
We call this the “orthogonality condition” for the traditional analysis as it is similar to the “orthogonality condition” in
a two-way ANOVA, ie, sample sizes in the different cells have to be proportional (in our case, nT⊕∕nT = nC⊖∕nC) in order
to distinguish between the different effects.16 This will also solve Problem 2 as setting r2 = p⊕ leads to E[𝜇BM − 𝜇R] =
p(1−p)(s+ t− 1)(𝜇T+ −𝜇C+ − (𝜇T− −𝜇C−)) so that if t = s = 0.5, E[𝜇BM − 𝜇R] = 0. Hence, we do not observe a difference
between the means of the biomarker-led arm and the randomised arm if the biomarker assay is of no use at all. We also
solve Problem 3, as r2 is now fixed to p⊕.
In general, the expected difference between the mean of the biomarker-led arm and the randomised arm can now only
be zero if (a) p = 0 or p = 1, (b) s + t = 1, or (c) 𝜇T+ −𝜇C+ − (𝜇T− −𝜇C−) = 0. Case (a) refers to a situation where there are
no subgroups to distinguish as every patients is either truly positive or truly negative, case (b) refers to a situation where
the biomarker assay is of no use to distinguish between truly positive and truly negative patients, and case (c) refers to a
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situation where there is no treatment-by-biomarker interaction effect. While setting r2 to p⊕ fixes the problems regarding
the traditional analysis, in practice, the value of p⊕ is often unknown. Hence, a different method that is robust to the
choice of r2 is preferable. Furthermore, theremight be other reasons (ethical or financial) why a different value of r2 might
be chosen.
5 ALTERNATIVE ANALYSIS METHOD
In order to overcome the abovementioned disadvantage of the traditional analysis method, we propose a different way
to analyse the data obtained from a biomarker-strategy design by defining three test statistics that clearly distinguish
between the treatment effect, the (so-called) biomarker effect, and the interaction effect.
5.1 Hypotheses
We define the following three effects: (1) the treatment effect, (2) the biomarker effect, and (3) the interaction effect with
corresponding null hypotheses
HT0 ∶ 𝜇T − 𝜇C = p𝜇T+ + (1 − p)𝜇T− −
(
p𝜇C+ + (1 − p)𝜇C−
)
= 0, (2)
HB0 ∶
𝜇T+ + 𝜇C+
2 −
𝜇T− + 𝜇C−
2 = 0, (3)
HI0 ∶
𝜇T+ − 𝜇C+
2 −
𝜇T− − 𝜇C−
2 = 0. (4)
5.2 Test statistics for the treatment, biomarker, and interaction effect
5.2.1 Test statistic for the treatment effect
The two means 𝜇T and 𝜇C can be estimated directly from the design by 1nT
∑
T𝑦 = ZTR and
1
nC
∑
C𝑦 = ZCR, respectively.
Hence, we can define a test statistic for the treatment effect as follows:
TT =
ZTR − ZCR√
V̂AR [ZTR − ZCR]
. (5)
The expected value and variance of the test statistic as well as an estimator for the variance are given in Appendix B.
5.2.2 Test statistics for the biomarker and the interaction effect
In the following, we derive test statistics for the biomarker and the interaction effect. Note that the null hypotheses for
the biomarker and the interaction effect depend on the means 𝜇T+ , 𝜇C+ , 𝜇T− , and 𝜇C− , which cannot be estimated directly
from the design. However, it is possible to rewrite the null hypotheses in such a way that only parameters that can be
estimated directly from the data are involved. Let 𝜃T⊕ denote the true mean of the biomarker-led treatment arm, and let
𝜃C⊖ denote the true mean of the biomarker-led control arm (see Table 1). It can be shown that in the case that there is no
biomarker (interaction) effect, the following expressions are true:
HB0 ∶
𝜇T+ + 𝜇C+
2 −
𝜇T− + 𝜇C−
2 = 0
⇐⇒ HB0 ∶ 𝜃T⊕ − 𝜇T(pt + (1 − p)(1 − s)) − (𝜃C⊖ − 𝜇C(p(1 − t) + s(1 − p))) = 0
(6)
HI0 ∶
𝜇T+ − 𝜇C+
2 −
𝜇T− − 𝜇C−
2 = 0
⇐⇒ HI0 ∶ 𝜃T⊕ − 𝜇T(pt + (1 − p)(1 − s)) + (𝜃C⊖ − 𝜇C(p(1 − t) + s(1 − p))) = 0.
(7)
Now, let ZT and ZC be defined as follows:
ZT =
∑
T⊕
𝑦 −
nT⊕
nT
∑
T
𝑦 (8)
ZC =
∑
C⊖
𝑦 −
nC⊖
nC
∑
C
𝑦. (9)
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It can be shown that the left-hand side of Equations 6 and 7 can be estimated by (ZT − ZC) ∕ (Nr1) and (ZT + ZC) ∕ (Nr1),
respectively. Hence, a test statistic for the biomarker effect is given by
TB =
ZT − ZC√
V̂AR [ZT − ZC]
(10)
and for the interaction effect by
TI =
ZT + ZC√
V̂AR [ZT + ZC]
. (11)
The expected values and variances as well as estimators for the variances can be found in Appendix C.
5.3 Multiple testing
In cases where little is known about the new treatment under investigation and/or the biomarker used, it might be desir-
able to testmore than one hypotheses within the same trial. For example, wemight be interested in simultaneously testing
the treatment and the interaction effect. Let COVT,B, COVT,I, and COVB,I denote the covariances between the test statis-
tics for the treatment and the biomarker effect (T,B), the treatment and the interaction effect (T,I), and the biomarker and
the interaction effect (B,I). The expected values of the covariances are given by
COVT,B = −
√
Nr1
(
𝜎2T(1 − r2)(pt + (1 − p)(1 − s)) + 𝜎
2
Cr2(p(1 − t) + (1 − p)s)
)√
(1 − r1)r2(1 − r2) (VAR [ZT] + VAR [ZC] − 2COV [ZT ,ZC])
(
r2𝜎2C + (1 − r2)𝜎
2
T
) (12)
COVT,I = −
√
Nr1
(
𝜎2T(1 − r2)(pt + (1 − p)(1 − s)) − 𝜎
2
Cr2(p(1 − t) + (1 − p)s)
)√
(1 − r1)r2(1 − r2) (VAR [ZT] + VAR [ZC] + 2COV [ZT ,ZC])
(
r2𝜎2C + (1 − r2)𝜎
2
T
) (13)
COVB,I =
VAR [ZT] − VAR [ZC]√
VAR [ZT − ZC]
√
VAR [ZT + ZC]
. (14)
Let T denote the vector containing the three test statistics for the treatment, biomarker, and interaction effect with
T =
( TT
TB
TI
)
approx.∼ N (𝜇,Σ)
with
𝜇 =
( E [TT]
E [TB]
E [TI]
)
,Σ =
( 1
COVT,B 1
COVT,I COVB,I 1
)
.
Functions like qmvnorm from the R-Package mvtnorm or the Mata function ghk() from Stata can be used in order to
find the adjusted critical values to control the overall type I error rate. However, in the following, we focus on testing the
interaction effect only, so no adjustment is made.
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5.4 Sample size calculation
In the following, we give formulae to approximately calculate the sample sizes to test the different hypotheses given above.
To simplify the notation, let 𝜎T, 𝜎C, 𝜎T⊕ , 𝜎T⊖ , A, B, and C be defined as follows:
𝜎2T = p
(
𝜇2T+ + 𝜎
2
T+
)
+ (1 − p)
(
𝜇2T− + 𝜎
2
T−
)
− 𝜇2T
𝜎2C = p
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)
(
𝜇2C−
+ 𝜎2C−
)
− 𝜇2C
𝜎2T⊕ = pt
(
𝜇2T+ + 𝜎
2
T+
)
+ (1 − p)(1 − s)
(
𝜇2T− + 𝜎
2
T−
)
− 𝜃2T⊕
𝜎2C⊖
= p(1 − t)
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)s
(
𝜇2C−
+ 𝜎2C−
)
− 𝜃2C⊖
A =
𝜎2T⊕
+ 𝜎2C⊖ + p⊕p⊖
(
𝜇2T + 𝜇
2
C
)
− 2
(
p⊖𝜇T𝜃T⊕ + p⊕𝜇C𝜃C⊖
)
r1
+
(1 − r2)p2⊕𝜎2T + r2p
2
⊖𝜎
2
C
(1 − r1)r2(1 − r2)
B =
r1r2p⊕p⊖𝜎2C + r1(1 − r2)p⊕p⊖𝜎
2
T
(1 − r1)r2(1 − r2)
C = −𝜃T⊕𝜃C⊖ − p⊕p⊖𝜇T𝜇C + p⊖𝜇C𝜃T⊕ + p⊕𝜇T𝜃C⊖.
The following equations give the sample sizes required to detect a certain effect for the traditional analysis (NTR), the
treatment effect (NT), the biomarker effect (NB), and the interaction effect (NI) based on a two two-sided test with type I
error 𝛼 and power 1 − 𝛽:
NTR ≈
( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ + 𝜃C⊖ − (r2𝜇T + (1 − r2)𝜇C)
)2(𝜎2T⊕ + 𝜎2C⊖ − 2𝜃T⊕𝜃C⊖
r1
+
r2𝜎2T + (1 − r2)𝜎
2
C
1 − r1
)
(15)
NT ≈
(z1−𝛼∕2 + z1−𝛽
𝜇T − 𝜇C
)2 (1 − r2)𝜎2T + r2𝜎2C
(1 − r1)r2(1 − r2)
(16)
NB ≈
( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ − 𝜃C⊖ − p⊕𝜇T + p⊖𝜇C
)2( r1A − 2C
2r1
)
+
√( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ − 𝜃C⊖ − p⊕𝜇T + p⊖𝜇C
)4( r1A − 2C
2r1
)2
+
( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ − 𝜃C⊖ − p⊕𝜇T + p⊖𝜇C
)2 B
r21
(17)
NI ≈
( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ + 𝜃C⊖ − p⊕𝜇T − p⊖𝜇C
)2( r1A + 2C
2r1
)
+
√( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ + 𝜃C⊖ − p⊕𝜇T − p⊖𝜇C
)4( r1A + 2C
2r1
)2
+
( z1−𝛼∕2 + z1−𝛽
𝜃T⊕ + 𝜃C⊖ − p⊕𝜇T − p⊖𝜇C
)2 B
r21
(18)
It can be seen that all sample sizes depend on the randomisation ratios r1 and r2. Optimal solutions can be found using
a grid search.
5.5 Point estimators and confidence intervals
The test statistic for the interaction effect does not provide an answer to whether the interaction is quantitative (i.e., the
treatment effect for biomarker-positive and biomarker-negative patients points in the same direction but has a different
magnitude) or qualitative (i.e., the treatment effects for the two subgroups point in different directions). Hence, we derive
point estimators and confidence intervals for the treatment effects 𝜇T+ − 𝜇C+ and 𝜇T− − 𝜇C− for the biomarker-positive
and biomarker-negative patients, respectively. In the following, we assume that the true values of the prevalence p,
the sensitivity t, and the specificity s are known (or can be estimated from a different trial). The treatment effects for
biomarker-positive and biomarker-negative patients can be estimated by
?̂?T+ − ?̂?C+ =
1
Nr1
∑
T⊕ > 𝑦 +
1
Nr1
∑
C⊖𝑦 − (1 − s)
1
nT
∑
T𝑦 − s
1
nC
∑
C𝑦
p(t + s − 1) , (19)
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?̂?T− − ?̂?C− = −
1
Nr1
∑
T⊕𝑦 +
1
Nr1
∑
C⊖𝑦 − t
1
nT
∑
T𝑦 − (1 − t)
1
nC
∑
C𝑦
(1 − p)(t + s − 1) . (20)
Assuming that the estimators approximately follow a normal distribution, (1 − 𝛼)% confidence intervals are given by[
?̂?T+ − ?̂?C+ − z1−𝛼∕2
√
V̂AR
[
?̂?T+ − ?̂?C+
]
, ?̂?T+ − ?̂?C+ + z1−𝛼∕2
√
V̂AR
[
?̂?T+ − ?̂?C+
]]
(21)[
?̂?T− − ?̂?C− − z1−𝛼∕2
√
V̂AR
[
?̂?T− − ?̂?C−
]
, ?̂?T− − ?̂?C− + z1−𝛼∕2
√
V̂AR
[
?̂?T− − ?̂?C−
]]
(22)
with
V̂AR
[
?̂?T+ − ?̂?C+
]
= 1
(p(t + s − 1))2
⎛⎜⎜⎜⎝
Nr1
∑
T⊕𝑦
2 −
(∑
T⊕𝑦
)2
(Nr1)2(Nr1 − 1)
+
Nr1
∑
C⊖𝑦
2 −
(∑
C⊖𝑦
)2
(Nr1)2(Nr1 − 1)
+
(1 − s)2s2T
nT
+
s2s2C
nC
− 2
(Nr1)2(Nr1 − 1)
∑
T⊕
𝑦
∑
C⊖
𝑦
) (23)
V̂AR
[
?̂?T− − ?̂?C−
]
= 1
((1 − p)(t + s − 1))2
⎛⎜⎜⎜⎝
Nr1
∑
T⊕𝑦
2 −
(∑
T⊕𝑦
)2
(Nr1)2(Nr1 − 1)
+
Nr1
∑
C⊖𝑦
2 −
(∑
C⊖𝑦
)2
(Nr1)2(Nr1 − 1)
+
t2s2T
nT
+
(1 − t)2s2C
nC
− 2
(Nr1)2(Nr1 − 1)
∑
T⊕
𝑦
∑
C⊖
𝑦
)
.
(24)
The derivations can be found in the Supporting Information where we also provide the covariance between the two
estimators allowing for the construction of joint confidence regions.
6 RESULTS
In order to be able to compare the traditional and the alternative analysis method, we set r2 = p⊕. As shown in Section
4.2, this will ensure that the traditional analysis method provides a test statistic for the interaction effect only. On the basis
of the results for the AZISAST trial (see Section 2), we calculated the sample sizes to test the interaction effect using the
traditional and the alternative analysis method for different values of the prevalence p (from 0 to 1 in steps of 0.01) and
the sensitivity t and specificity s (from 0.5 to 1 in steps of 0.1) for a two-sided type I error of 𝛼 = 0.05 and a power of 80%.
In the following, we focus on testing the interaction effect only (instead of testing the treatment, the biomarker, and the
interaction effect simultaneously), so no adjustment for the significance level is made. For the traditional analysis, r2 is
set to p⊕ (as explained in Section 4.2). In order to find the optimal value for r1, we calculated the sample sizes for values
of r1 from 0 to 1 in steps of 0.01. The randomisation ratio r1 is then chosen so that the resulting sample size is minimised.
Obviously, choosing smaller increments will yield a more accurate value for r1. For the alternative analysis method, we
used a grid search over r1 and r2 (from 0 to 1 in steps of 0.01). For each combination of r1 and r2, we calculated the resulting
sample sizes and chose the combination that minimises the sample size for given values of p, t, and s. In order to verify
the obtained sample sizes, we simulated 10 000 data sets and estimated the resulting type I error and power for different
scenarios (see Appendix D).
6.1 Results for the traditional analysis to test the interaction effect
The left-hand side of Figure 2 shows the minimal sample sizes needed for the traditional analysis depending on the
prevalence p, the sensitivity t, and the specificity s for the AZISAST trial. The black solid line shows the sample sizes for
a perfect biomarker assay, the grey solid line for a biomarker assay with t = s = 0.9, and the black dashed line for a
biomarker assay with t = s = 0.8. The labels show the values for the randomisation ratios r1 and r2 with the value of r1
being the optimal value for r2 = p⊕.
As expected, we see that the sample size for the perfect assay is smaller than the sample sizes for an imperfect assay with
the sample size getting larger the smaller the values for t and s. We also see that the sample size increases with smaller and
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FIGURE 2 Minimal sample sizes to test the interaction effect using the traditional and alternative analysis method depending on the
prevalence p, the sensitivity t, the specificity s, and the randomisation ratios r1 and r2
larger values for the prevalence p. The sample size for the traditional analysis is smallest for a perfect assay, a prevalence
of p = 0.5, and randomisation ratios of r1 = 0.47 and r2 = 0.5. In this case, only 142 patients would be needed. If the
prevalence is 0.15, the sample size increases to 516 for the perfect biomarker assay.
For an imperfect assay with t = s = 0.9, the sample size is 231 for a prevalence of 0.5, and hence, in comparison to
a perfect assay, we already need nearly 90 patients more. For a prevalence of 0.15, the sample size increases to 853, and
therefore, nearly 340 more patients are needed in comparison with the perfect assay. The sample sizes are even larger
when the sensitivity and specificity are 0.8. In this case, 423 patients are needed if p = 0.5 and 1580 if p = 0.15. Compared
with the case of a perfect assay, the sample sizes approximately triple.
In general, it should be noted that the optimal value for r1 is not necessarily 0.5 but varies between 0.47 and 0.51.
However, for a prevalence between 0.05 and 0.95, the difference in sample sizes for the optimal value of r1 and r1 = 0.5
is less than one patient. Therefore, in most cases, r1 can be set to 0.5 without a noticeable change in the sample size.
6.2 Results for the alternative method to test the interaction effect
In the following, we show the results for the sample sizes for testing the interaction effect based on our proposed analysis
method. The right-hand side of Figure 2 shows the resulting sample sizes for the interaction effect. As before, the black
solid line shows the sample sizes for the perfect biomarker assay, the grey solid line for an assay with t = s = 0.9, and
the black dashed line for an assay with t = s = 0.8. Labels show the optimal values for r1 and r2 so that the sample size
is minimised for given values of p, t, and s.
Again, we see that the sample sizes are smaller for prevalences around 0.5 and increase towards smaller and larger
values. For example, for a perfect assay and a prevalence of 0.5, the minimal sample size for the interaction effect is 142.
It increases to 250 if the prevalence is 0.25 and to 530 if the prevalence is only 0.15. We also see that (as expected) larger
sample sizes are needed if the assay is not perfect. For example, for an imperfect assay with t = s = 0.9, the minimal
sample sizes are 231 (for p = 0.5), 400 (for p = 0.25), and 836 (for p = 0.15). For an imperfect assay with t = s = 0.8,
the following sample sizes result 422 (for p = 0.5), 722 (for p = 0.25), and 1498 (for p = 0.15).
As for the traditional analysis, we note that the optimal value for the randomisation ratio r2 is r2 = p⊕. However,
while this is a requirement for the traditional analysis in order for the results to be interpretable (see Section 4.2), for the
interaction effect setting r2 to p⊕ minimises the sample size but is not necessary in order to interpret the results of the
test statistic.
We also see that the optimal value for r1 is not necessarily 0.5 but ranges between 0.47 and 0.5. Again, the differences
between the minimal sample size and the one obtained for r1 = 0.5 is less than one patient as long as the second ran-
domisation ratio r2 is chosen so that the sample size is minimised given r1. The situation changes noticeably if both
randomisation rules are set to 0.5, which is frequently done. Let N0.5,0.5 denote the sample size for the interaction effect
for r1 = r2 = 0.5 and letNmin denote theminimal sample size. Figure 3 shows the absolute difference in the sample sizes
(N0.5,0.5 − Nmin, left-hand side) and the relative differences (N0.5,0.5∕Nmin, right-hand side). As we can see, the absolute
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differences vary between 0 and approximately 130 (for a prevalence between 0.15 and 0.85). The absolute difference is
even larger for smaller (and higher) values of the prevalence. While we see that the absolute difference of the sample sizes
does not depend on the sensitivity and specificity of the biomarker, we see that the relative difference does (see right-hand
side of Figure 3). The highest relative differences occur for the perfect biomarker assay (as this has the smallest minimal
sample size). Figure 4 shows the absolute differences in sample size for the traditional analysis and the alternative analy-
sis for the interaction effect (left-hand side) as well as the relative differences in sample size in percent (right-hand side)
. As we can see, the sample size for the traditional analysis is often higher than the sample size for the interaction effect
(except for a perfect biomarker assay where the sample size for the traditional design is always lower than the sample size
for the interaction effect). The absolute difference in the sample size might be substantial: for example, for t = s = 0.7
and p = 0.15, the absolute difference in sample size is 268. The relative increase in the sample size is about 8% (from
NI = 3388 to NTR = 3656). We can also see that in cases where the sample size for the traditional analysis is smaller
than the sample size for the interaction effect, the increase in sample size is less than 3%. For example, for t = s = 1 and
p = 0.15, the sample size increases from NTR = 516 to NI = 530.
FIGURE 3 Difference in sample sizes to test the interaction effect using the alternative analysis method with r1 = r2 = 0.5 or the optimal
randomisation ratios depending on the prevalence p, the sensitivity t, the specificity s, and the randomisation ratios r1 and r2
FIGURE 4 Differences in sample sizes to test the interaction effect using the traditional and alternative analysis method depending on the
prevalence p, the sensitivity t, and the specificity s
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7 CONCLUSION
This paper investigates the performance of the traditional analysis of the biomarker-strategy design. We derive optimal
randomisation rules in order to minimise the sample size for the traditional analysis. We also propose a different analysis
method for the data obtained from such a design and explore the properties of this method.
The traditional analysis has been criticisedmany times.2,9,17,18 Themain problem is that the traditional analysis does not
distinguish between the treatment and the interaction effect. Hence, it is possible to observe no difference between the
mean of the biomarker-led arm and the randomised arm even if there is an interaction effect or to observe a difference
between the means even if there is no interaction effect. We show that if the sample sizes in the four subgroups of the
biomarker-strategy design fulfil the “orthogonality condition” (ie, are proportional to each other), the abovementioned
problems can be solved. However, while the “orthogonality condition” ensures that the traditional analysis provides a
test statistic for the interaction effect only, the value of p⊕ is often not known as it depends on the true values for the
sensitivity, the specificity, and the prevalence. These values are often unknown at the planning stage of a trial.
To overcome the disadvantages of the traditional analysis, we propose a different analysis method based on the work
of Rücker.11 We define three different effects than can be measured within the biomarker-strategy design: the treatment
effect, the biomarker effect, and the interaction effect. This ensures that our analysis can clearly distinguish between the
treatment effect and the interaction effect, regardless of the randomisation rules used. We derive test statistics and show
how the sample sizes for the three effects can be calculated. Optimal randomisation rules are derived in order tominimise
the sample sizes.We also provide point estimators and confidence intervals for the treatment effects in the two subgroups.
Furthermore, we show that if the “orthogonality condition” is fulfilled, the sample size for the interaction effect (based
on the alternative analysis method) is often smaller than the sample size for the traditional analysis. In cases where the
sample size for the alternative analysis method is larger than the sample size for the traditional analysis, the difference is
less than 3% of the sample size and therefore often negligible. In general, we therefore recommend to use the alternative
analysis method instead of the traditional analysis method.
It should be noted that the biomarker-strategy design is less efficient than the biomarker-stratified design. Shih and
Lin19 recently published an evaluation of the relative efficiency comparing the variances of the two designs with each
other. They conclude that the biomarker-strategy design is less efficient than the biomarker-stratified design,which comes
as no surprise given that the biomarker-stratified design contains more information. While the qualitative conclusion of
Shih and Lin is correct (ie, the biomarker-stratified design is more efficient than the biomarker-strategy design), their
quantitative results are based on setting r2 equal to 0.5. As we have shown, this choice will not lead to the most efficient
design (see Section 6.2). Hence, it remains to be seen how much more efficient the biomarker-stratified design is as
compared to the biomarker-strategy design if optimal randomisation rules are used.
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APPENDIX A: TRADITIONAL ANALYSIS
The expected value and variance of the test statistic for the traditional analysis are given by
E [ZBM − ZR] = (t − r2)p
(
𝜇T+ − 𝜇C+
)
+ (1 − s − r2)(1 − p)
(
𝜇T− − 𝜇C−
)
= tp
(
𝜇T+ − 𝜇C+
)
+ (1 − s)(1 − p)
(
𝜇T− − 𝜇C−
)
− r2
(
p
(
𝜇T+ − 𝜇C+
)
+ (1 − p)
(
𝜇T− − 𝜇C−
)) (A1)
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VAR [ZBM − ZR] =
pt
(
𝜇2T+
+ 𝜎2T+
)
+ (1 − p)(1 − s)
(
𝜇2T−
+ 𝜎2T−
)
−
(
pt𝜇T+ + (1 − p)(1 − s)𝜇T−
)2
Nr1
+
p(1 − t)
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)s
(
𝜇2C−
+ 𝜎2C−
)
−
(
p(1 − t)𝜇C+ + (1 − p)s𝜇C−
)2
Nr1
−
2
(
tp𝜇T+ + (1 − p)(1 − s)𝜇T−
) (
(1 − t)p𝜇C+ + s(1 − p)𝜇C−
)
Nr1
+
[
p
(
𝜇2T+
+ 𝜎2T+ −
(
𝜇2C+
+ 𝜎2C+
))
+ (1 − p)
(
𝜇2T−
+ 𝜎2T− −
(
𝜇2C−
+ 𝜎2C−
))]
r2
N(1 − r1)
−
[
(p𝜇T+ + (1 − p)𝜇T−)2 − (p𝜇C+ + (1 − p)𝜇C−)2
]
r2
N(1 − r1)
+
p
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)
(
𝜇2C−
+ 𝜎2C−
)
−
(
p𝜇C+ + (1 − p)𝜇C−
)2
N(1 − r1)
.
(A2)
The variance can be estimated by
V̂AR [ZBM − ZR] =
∑
T⊕𝑦
2 −
(∑
T⊕𝑦
)2
−
∑
T⊕𝑦
2
Nr1−1
+
∑
C⊖𝑦
2 −
(∑
C⊖𝑦
)2
−
∑
C⊖𝑦
2
Nr1−1
− 2
∑
T⊕𝑦
∑
C⊖𝑦
Nr1
(Nr1)2
+
N(1 − r1)r2
∑
T𝑦
2 −
(∑
T𝑦
)2
(N(1 − r1))2
+
N(1 − r1)(1 − r2)
∑
C𝑦
2 −
(∑
C𝑦
)2
(N(1 − r1))2
.
(A3)
In the following, we show that by setting r2 = p⊕, the traditional analysis method provides a test statistic for the
interaction effect. According to Equation A1, the expected value is given by
E [ZBM − ZR] = tp
(
𝜇T+ − 𝜇C+
)
+ (1 − s)(1 − p)
(
𝜇T− − 𝜇C−
)
− r2
(
p
(
𝜇T+ − 𝜇C+
)
+ (1 − p)
(
𝜇T− − 𝜇C−
))
=
(
𝜇T+ − 𝜇C+
)
p (t − r2) −
(
𝜇T− − 𝜇C−
)
(1 − p) (r2 − 1 + s)
r2=p⊕=
(
𝜇T+ − 𝜇C+
)
p (t − pt − (1 − p)(1 − s)) −
(
𝜇T− − 𝜇C−
)
(1 − p) (pt + (1 − p)(1 − s) − 1 + s)
= 2p(1 − p)(t + s − 1)
(𝜇T+ − 𝜇C+
2 −
𝜇T− − 𝜇C−
2
)
.
(A4)
APPENDIX B: TREATMENT EFFECT
The expected value and true variance of the test statistic for the treatment effect are given by
E [ZTR − ZCR] = p
(
𝜇T+ − 𝜇C+
)
+ (1 − p)
(
𝜇T− − 𝜇C−
)
(B5)
VAR [ZTR − ZCR] =
p
(
𝜇2T+
+ 𝜎2T+
)
+ (1 − p)
(
𝜇2T−
+ 𝜎2T−
)
− (p𝜇T+ + (1 − p)𝜇T−)2
N(1 − r1)r2
+
p
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)
(
𝜇2C−
+ 𝜎2C−
)
− (p𝜇C+ + (1 − p)𝜇C−)2
N(1 − r1)(1 − r2)
.
(B6)
The variance can be estimated by
V̂AR [ZTR − ZCR] = =
∑
T𝑦
2 − 1N(1−r1)r2
(∑
T𝑦
)2
(N(1 − r1)r2)(N(1 − r1)r2 − 1)
+
∑
C𝑦
2 − 1N(1−r1)(1−r2)
(∑
C𝑦
)2
(N(1 − r1)(1 − r2))(N(1 − r1)(1 − r2) − 1) .
(B7)
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APPENDIX C: BIOMARKER AND INTERACTION EFFECT
The expected values are given by
E [ZT] = Nr1𝜃T⊕ − Nr1𝜇T(pt + (1 − p)(1 − s)) (C8)
E [ZC] = Nr1𝜃C⊖ − Nr1𝜇C(p(1 − t) + s(1 − p)). (C9)
The true variances are given by
VAR [ZT] = Nr1
(
pt
(
𝜇2T+ + 𝜎
2
T+
)
+ (1 − p)(1 − s)
(
𝜇2T− + 𝜎
2
T−
)
− (pt𝜇T+ + (1 − p)(1 − s)𝜇T−)
2
)
+ Nr1p+(1 − p+)𝜇2T + ((Nr1p+)
2 + Nr1p+(1 − p+))
𝜎2T
N(1 − r1)r2
− 2
(
Nr1𝜇T(tp𝜇T+ + (1 − p)(1 − s)𝜇T−)(1 − p+)
) (C10)
VAR [ZC] = Nr1
(
p(1 − t)
(
𝜇2C+
+ 𝜎2C+
)
+ (1 − p)s
(
𝜇2C−
+ 𝜎2C−
)
− (p(1 − t)𝜇C+ + (1 − p)s𝜇C−)
2
)
+ Nr1p−(1 − p−)𝜇2C +
(
(Nr1p−)2 + Nr1p−(1 − p−)
) 𝜎2C
N(1 − r1)(1 − r2)
− 2
(
Nr1𝜇C((1 − t)p𝜇C+ + (1 − p)s𝜇C−)(1 − p−)
) (C11)
and the true covariance by
COV [ZT ,ZC] = Nr1
(
−
(
tp𝜇T+ + (1 − p)(1 − s)𝜇T−
) (
(1 − t)p𝜇C+ + s(1 − p)𝜇C−
)
− p⊕p⊖𝜇T𝜇C
+ p⊖𝜇C
(
tp𝜇T+ + (1 − p)(1 − s)𝜇T−
)
+ p⊕𝜇T
(
(1 − t)p𝜇C+ + s(1 − p)𝜇C−
))
.
(C12)
The variances and covariances of ZT and ZC can be estimated as follows:
V̂AR [ZT] =
1
Nr1 − 1
⎛⎜⎜⎝Nr1
∑
T⊕
𝑦2 −
(∑
T⊕
𝑦
)2
+ Nr1nT⊕
(
nT⊕ − 1
) s2T
nT
+Nr1nT⊕
(
1 −
nT⊕
Nr1
)(
1
nT
∑
T
𝑦
)2
− 2Nr1
(
1 −
nT⊕
Nr1
)(∑
T⊕
𝑦
)(
1
nT
∑
T
𝑦
)⎞⎟⎟⎠
(C13)
V̂AR [ZC] =
1
Nr1 − 1
⎛⎜⎜⎝Nr1
∑
C⊖
𝑦2 −
(∑
C⊖
𝑦
)2
+ Nr1nC⊖
(
nC⊖ − 1
) s2C
nC
+Nr1nC⊖
(
1 −
nC⊖
Nr1
)(
1
nC
∑
C
𝑦
)2
− 2Nr1
(
1 −
nC⊖
Nr1
)(∑
C⊖
𝑦
)(
1
nC
∑
C
𝑦
)⎞⎟⎟⎠
(C14)
ĈOV [ZT ,ZC] =
1
Nr1 − 1
(
−
(∑
T⊕
𝑦
)(∑
C⊖
𝑦
)
+
(∑
T⊕
𝑦
)
nC⊖
(
1
nC
∑
C
𝑦
)
+
(∑
C⊖
𝑦
)
nT⊕
(
1
nT
∑
T
𝑦
)
− nT⊕nC⊖
(
1
nT
∑
T
𝑦
)(
1
nC
∑
C
𝑦
)) (C15)
The derivations can be found in the Supporting Information. We anticipate the test statistics to approximately follow a
normal distribution.
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APPENDIX D: SIMULATION RESULTS FOR THE TYPE I ERROR AND POWER
In order to verify the sample sizes obtained in Section 6, we simulated 10 000 data sets and estimated the resulting type
I error and power (Table D1). The power was estimated using the same values as described in Sections 2 and 6. For
the type I error, the means were set to 𝜇T+ = 90, 𝜇T− = 70, 𝜇C− = 75, and 𝜇C− = 55 (ie, assuming that there is no
interaction effect).
TABLE D1 Results for the power based on 10 000 simulations for different values of p, t, s, r1, and r2
Interaction effect Traditional analysis
p t s r1 r2 NI 𝜶 1 − 𝜷 r1 r2 NTrad 𝜶 1 − 𝜷
0.15 0.8 0.8 0.50 0.29 1498 0.0499 0.7927 0.51 0.29 1580 0.0520 0.8211
0.15 0.9 0.9 0.50 0.22 836 0.0510 0.7938 0.50 0.22 853 0.0466 0.8083
0.15 1.0 1.0 0.49 0.15 530 0.0475 0.7877 0.49 0.15 516 0.0482 0.7884
0.20 0.8 0.8 0.50 0.32 974 0.0518 0.7995 0.51 0.32 1015 0.0473 0.8147
0.20 0.9 0.9 0.49 0.26 541 0.0467 0.7939 0.50 0.26 549 0.0461 0.7985
0.20 1.0 1.0 0.49 0.20 341 0.0486 0.7964 0.48 0.20 333 0.0462 0.7795
0.25 0.8 0.8 0.49 0.35 722 0.0500 0.7892 0.50 0.35 745 0.0489 0.8065
0.25 0.9 0.9 0.49 0.30 400 0.0489 0.7967 0.49 0.30 404 0.0473 0.7963
0.25 1.0 1.0 0.48 0.25 251 0.0498 0.7943 0.48 0.25 246 0.0490 0.7876
0.30 0.8 0.8 0.49 0.38 584 0.0478 0.7987 0.50 0.38 598 0.0470 0.8086
0.30 0.9 0.9 0.49 0.34 322 0.0451 0.7900 0.49 0.34 325 0.0533 0.7986
0.30 1.0 1.0 0.48 0.30 201 0.0490 0.7925 0.48 0.30 198 0.0500 0.7830
0.35 0.8 0.8 0.49 0.41 503 0.0462 0.7912 0.50 0.41 512 0.0503 0.8029
0.35 0.9 0.9 0.49 0.38 277 0.0480 0.7870 0.49 0.38 278 0.0473 0.7982
0.35 1.0 1.0 0.48 0.35 172 0.0468 0.7757 0.48 0.35 170 0.0473 0.7697
0.40 0.8 0.8 0.49 0.44 455 0.0478 0.7904 0.50 0.44 461 0.0506 0.7994
0.40 0.9 0.9 0.48 0.42 250 0.0497 0.7829 0.49 0.42 251 0.0496 0.7891
0.40 1.0 1.0 0.47 0.40 154 0.0477 0.7882 0.47 0.40 154 0.0500 0.7787
0.45 0.8 0.8 0.49 0.47 430 0.0476 0.7856 0.49 0.47 433 0.0471 0.8060
0.45 0.9 0.9 0.48 0.46 235 0.0479 0.7817 0.49 0.46 236 0.0488 0.7902
0.45 1.0 1.0 0.47 0.45 145 0.0460 0.7799 0.47 0.45 145 0.0445 0.7885
0.50 0.8 0.8 0.49 0.50 422 0.0493 0.7967 0.49 0.50 423 0.0489 0.7974
0.50 0.9 0.9 0.48 0.50 231 0.0485 0.7865 0.48 0.50 231 0.0455 0.7795
0.50 1.0 1.0 0.47 0.50 142 0.0396 0.7636 0.47 0.50 142 0.0436 0.7613
0.55 0.8 0.8 0.49 0.53 430 0.0463 0.7922 0.49 0.53 430 0.0494 0.7858
0.55 0.9 0.9 0.48 0.54 235 0.0449 0.7841 0.48 0.54 235 0.0460 0.7834
0.55 1.0 1.0 0.47 0.55 145 0.0460 0.7809 0.47 0.55 145 0.0447 0.7870
0.60 0.8 0.8 0.49 0.56 455 0.0482 0.7939 0.49 0.56 454 0.0511 0.7959
0.60 0.9 0.9 0.48 0.58 250 0.0484 0.7847 0.48 0.58 249 0.0467 0.7791
0.60 1.0 1.0 0.47 0.60 154 0.0492 0.7966 0.47 0.60 154 0.0471 0.7973
0.65 0.8 0.8 0.49 0.59 503 0.0498 0.7998 0.49 0.59 501 0.0521 0.8003
0.65 0.9 0.9 0.49 0.62 277 0.0459 0.7881 0.49 0.62 275 0.0430 0.7891
0.65 1.0 1.0 0.48 0.65 172 0.0412 0.7645 0.48 0.65 170 0.0390 0.7657
0.70 0.8 0.8 0.49 0.62 584 0.0510 0.7985 0.49 0.62 582 0.0488 0.7921
0.70 0.9 0.9 0.49 0.66 322 0.0465 0.7908 0.49 0.66 320 0.0492 0.7888
0.70 1.0 1.0 0.48 0.70 201 0.0528 0.7974 0.48 0.70 198 0.0452 0.7855
0.75 0.8 0.8 0.49 0.65 722 0.0481 0.7958 0.49 0.65 720 0.0496 0.7915
0.75 0.9 0.9 0.49 0.70 400 0.0496 0.7942 0.49 0.70 396 0.0466 0.7875
0.75 1.0 1.0 0.48 0.75 251 0.0567 0.8028 0.48 0.75 246 0.0524 0.7891
0.80 0.8 0.8 0.50 0.68 974 0.0476 0.8042 0.50 0.68 974 0.0501 0.8010
0.80 0.9 0.9 0.49 0.74 541 0.0453 0.7931 0.49 0.74 536 0.0496 0.7895
(Continues)
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TABLE D1 (Continued)
Interaction effect Traditional analysis
p t s r1 r2 NI 𝜶 1 − 𝜷 r1 r2 NTrad 𝜶 1 − 𝜷
0.80 1.0 1.0 0.49 0.80 341 0.0524 0.7901 0.48 0.80 333 0.0475 0.7860
0.85 0.8 0.8 0.50 0.71 1498 0.0517 0.7920 0.50 0.71 1506 0.0509 0.8039
0.85 0.9 0.9 0.50 0.78 836 0.0505 0.7955 0.49 0.78 829 0.0558 0.7971
0.85 1.0 1.0 0.49 0.85 530 0.0481 0.7887 0.49 0.85 516 0.0475 0.7904
